相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)
Martin Spacek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2023)
PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
Naji Bou Zeid et al.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY (2023)
Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
Gian Matteo Rigolin et al.
HEMATOLOGICAL ONCOLOGY (2021)
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
Thomas E. Lew et al.
BLOOD ADVANCES (2021)
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Agnes Mattsson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
Anthony R. Mato et al.
BLOOD (2020)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sandra Eketorp Sylvan et al.
HAEMATOLOGICA (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E. Coutre et al.
HEMASPHERE (2018)
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013
Anna Asklid et al.
LEUKEMIA & LYMPHOMA (2017)
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Mazie Tsang et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
A. R. Mato et al.
ANNALS OF ONCOLOGY (2017)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
分享论文
